Ann Gidner
Chief Executive Officer chez ZICCUM AB
Profil
Ann Ulrika Gidner is currently the Chief Executive Officer at Ziccum AB and an Independent Director at Iconovo AB.
Previously, she served as the Chief Executive Officer at AcuCort AB, SelectImmune Pharma AB, SenzaGen AB, and Monocl AB.
She also held various director and principal positions at Albumedix A, Cambrex Corp., LANXESS Corp., Cambrex AB, and Novozymes Biopharma Sweden AB.
Additionally, she was the Director of Sales and Marketing at LANXESS Deutschland GmbH and the Life Science Director at Semcon Caran AB.
Ms. Gidner received a graduate degree and an MBA from the University of Lund.
Postes actifs de Ann Gidner
| Sociétés | Poste | Début |
|---|---|---|
| ICONOVO AB | Director/Board Member | 01/01/2021 |
| ZICCUM AB | Chief Executive Officer | 09/05/2022 |
Anciens postes connus de Ann Gidner
| Sociétés | Poste | Fin |
|---|---|---|
| SELECTIMMUNE PHARMA AB (PUBL) | Chief Executive Officer | 27/04/2022 |
| SENZAGEN AB | Director/Board Member | 01/01/2020 |
LANXESS Deutschland GmbH
 LANXESS Deutschland GmbH Chemicals: SpecialtyProcess Industries LANXESS Deutschland GmbH produces and sells chemicals. It operates as a subsidiary company. The company is headquartered in Cologne, Germany. | Sales & Marketing | - |
| CAMBREX CORPORATION | Corporate Officer/Principal | - |
Albumedix A/S
 Albumedix A/S Pharmaceuticals: MajorHealth Technology Albumedix A/S is a Danish biotechnology company. The private company is based in Copenhagen, Denmark. | Corporate Officer/Principal | - |
Formation de Ann Gidner
| University of Lund | Graduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 5 |
|---|---|
| SENZAGEN AB | Health Technology |
| ACUCORT AB | Health Technology |
| ICONOVO AB | Health Technology |
| ZICCUM AB | Health Technology |
| SELECTIMMUNE PHARMA AB (PUBL) | Health Technology |
| Entreprise privées | 9 |
|---|---|
Cambrex Corp.
 Cambrex Corp. Pharmaceuticals: GenericHealth Technology Cambrex Corp. engages in the provision of products, services, and technologies to accelerate and improve the development and commercialization of new and generic therapeutics. It supplies to innovator and generic pharmaceutical companies. Its products include generic and branded APIs, controlled substances, chiral compounds, high potency APIs, and advanced intermediates. The company was founded by Arthur Mendolia and Cyril C. Baldwin Jr. in 1981 and is headquartered in East Rutherford, NJ. | Health Technology |
LANXESS Corp.
 LANXESS Corp. Chemicals: SpecialtyProcess Industries LANXESS Corp. manufactures rubber, rubber chemicals and rubber products. It business units includes advanced industrial intermediates, additives, urethane systems, inorganic pigments, leather and saltigo. The firm engages in the development, manufacture and sale of plastics, rubber, specialty chemicals and intermediates. The company was founded in 2004 and is headquartered in Pittsburgh, PA. | Process Industries |
| Cambrex AB | |
LANXESS Deutschland GmbH
LANXESS Deutschland GmbH Chemicals: SpecialtyProcess Industries LANXESS Deutschland GmbH produces and sells chemicals. It operates as a subsidiary company. The company is headquartered in Cologne, Germany. | Process Industries |
Semcon Caran AB
 Semcon Caran AB Engineering & ConstructionIndustrial Services Semcon Caran AB provides engineering, product development and information, and training services. It offers automotive facelifts, design management, digital distribution, energy solutions, smart services and topic based authoring services. The company was founded in 1980 and is headquartered in Gothenburg, Sweden. | Industrial Services |
Novozymes Biopharma Sweden AB
 Novozymes Biopharma Sweden AB BiotechnologyHealth Technology Part of Repligen Corp., Novozymes Biopharma Sweden AB operates as a contract manufacturer of biological products. The private company is based in Lund, Sweden. The CEO of the Swedish company is Harald Skogman. Novozymes Biopharma Sweden was acquired by Repligen Corp. from Novozymes A/S on December 20, 2011 for $29.02 million. | Health Technology |
Monocl AB
 Monocl AB Internet Software/ServicesTechnology Services Monocl AB develops cloud-based stakeholder platform. Its areas include business development, valuation, and communication. The company was founded by Björn Carlsson and Tobias Thornblad in 2011 and is headquartered in Gothenburg, Sweden. | Technology Services |
Albumedix A/S
Albumedix A/S Pharmaceuticals: MajorHealth Technology Albumedix A/S is a Danish biotechnology company. The private company is based in Copenhagen, Denmark. | Health Technology |
| Inceptua GmbH |
